Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Lymphoma 7Breast Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia, Myeloid, Acute 5Multiple Myeloma 4Lymphoma, T-Cell, Cutaneous 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Leukemia 3Glioblastoma 3Brain Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Recurrence 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Oligodendroglioma 2Neoplasms 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Mycosis Fungoides 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2

Interventions

pembrolizumab 1eicosapentaenoic acid ethyl ester 1eicosapentaenoic acid ethanolamide 1binimetinib 1Vorinostat 1Tamoxifen 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Fulvestrant 1Dasatinib 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Anatomic Stage IV Breast Cancer AJCC v8 × Vorinostat × Clear all
NCT04190056 2023-08-31

Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer

University of California, San Francisco

Phase 2 Terminated
1 enrolled 4 charts
Breast

Anatomic Stage IV Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡